This led to the selection of patients with adenocarcinoma histology and EGFR alterations and, in 2009, a landmark Phase III Iressa Pan-Asia Study (IPASS) identified clinical responsiveness and increased progression-free survival in EGFR mutant patients who received gefitinib as compared to standard chemotherapy [50]. Here, EGFR is linked to adenocarcinoma.